Metabolic activation of drugs by cytochrome P450 enzymes: Biochemical insights into mechanism-based inactivation by fibroblast growth factor receptor inhibitors and chemical approaches to attenuate reactive metabolite formation-Reference-Cited by-同舟云学术

Metabolic activation of drugs by cytochrome P450 enzymes: Biochemical insights into mechanism-based inactivation by fibroblast growth factor receptor inhibitors and chemical approaches to attenuate reactive metabolite formation

Published:2022-12 Issue: Volume:206 Page:115336
ISSN:0006-2952
Container-title:Biochemical Pharmacology
language:en
Short-container-title:Biochemical Pharmacology

Author:

Tang Lloyd Wei Tat,Chan Eric Chun Yong

Funder

Ministry of Education - Singapore

National University of Singapore

Publisher

Elsevier BV

Subject

Pharmacology,Biochemistry

Reference113 articles.

1. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients;Pirmohamed;BMJ.,2004

2. Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies;Impicciatore;Br. J. Clin. Pharmacol.,2001

3. Clinical and economic burden of adverse drug reactions;Sultana;J. Pharmacol. Pharmacother.,2013

4. Adverse drug event monitoring at the food and drug administration: Your report can make a difference;Ahmad;J. Gen. Intern. Med.,2003

5. Can the pharmaceutical industry reduce attrition rates?;Kola;Nat. Rev. Drug Discov.,2004

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanism-based inactivation of cytochromes P450: implications in drug interactions and pharmacotherapy;Xenobiotica;2024-08-28

2. The Drug-Drug Interaction between Erlotinib and OSI-930 Is Mediated through Aldehyde Oxidase Inhibition;Drug Metabolism and Disposition;2024-06-18

3. Probe Substrate Dependencies in CYP3A4 Allosteric Inhibition: A Novel Molecular Mechanism Involving F–F′ Loop Perturbations;Journal of Chemical Information and Modeling;2024-03-08

4. Kinase Inhibitors FDA Approved 2018–2023: Drug Targets, Metabolic Pathways, and Drug-Induced Toxicities;Drug Metabolism and Disposition;2024-01-29

5. Real-time fluorescent monitoring of phase I xenobiotic-metabolizing enzymes;RSC Advances;2024